dm+d

Unassigned

New Medicines

Alzheimer's disease - prevention in cognitively healthy subjects that are genetically predisposed to the disease

Information

New molecular entity
Roche
Roche

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

Anti-amyloid-beta (Aβ) monoclonal antibody
Alzheimers disease is the most common form of dementia, accounting for 50%-60% of all cases. The prevalence of dementia is below 1% in individuals aged 60-64 years, but shows an almost exponential increase with age, so that in people aged 85 years or older the prevalence is between 24% and 33% in the Western world.
Alzheimer's disease - prevention in cognitively healthy subjects that are genetically predisposed to the disease
also IV infusion
Subcutaneous injection